Twist Bioscience
TWST
201 hedge funds and large institutions have $957M invested in Twist Bioscience in 2023 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 75 increasing their positions, 46 reducing their positions, and 31 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 46
54% more call options, than puts
Call options by funds: $4.69M | Put options by funds: $3.05M
13% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 31
3.95% more ownership
Funds ownership: 107.46% → 111.42% (+4%)
2% more funds holding
Funds holding: 198 → 201 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less capital invested
Capital invested by funds: $1.43B → $957M (-$476M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$18.8M |
| 2 |
BlackRock
New York
|
+$16M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13.4M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
+$10.8M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$34.2M |
| 2 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$31.8M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$16.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.75M |
TWST Hedge Fund Activity: Q1 2023 in Review
201 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q1 2023, worth a combined $957M — down 33% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new TWST positions and 31 closed out — a net gain of 4 holders — while 75 added to existing stakes and 46 trimmed.
The largest buyer was State Street, adding an estimated $18.8M. The largest seller was VOYA Investment Management, cutting an estimated $34.2M.
- 201 institutional investors held Twist Bioscience (TWST) as of Q1 2023, up from 198 in Q4 2022.
- Funds reported $957M of Twist Bioscience stock for Q1 2023, down 33% quarter-over-quarter.
- 35 funds opened new Twist Bioscience positions in Q1 2023 and 31 closed out, a net change of +4 holders.
- The largest Twist Bioscience buyer in Q1 2023 was State Street, an estimated $18.8M added.
- The largest Twist Bioscience seller in Q1 2023 was VOYA Investment Management, an estimated $34.2M sold.
Based on aggregated 13F filings for Q1 2023.